Global Pulmonary Arterial Hypertension Market, by Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), by Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 5,821.90 million in 2018, and is expected to exhibit a CAGR of 5.9%, over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing incidence of chronic lung or heart problems are expected to drive growth of the pulmonary arterial hypertension market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2014, in the U.S. an estimated prevalence of one or two cases of pulmonary hypertension occurs in every 1 million U.S. population. Centers for Disease Control and Prevention (CDC), also reports that idiopathic pulmonary hypertension exist about 40.0% of all the cases, whereas the prevalence of the disease among patients with systemic sclerosis is about 10.0%, with sickle cell disease is about 3.0%, and among HIV patients is 0.5%. Furthermore, the Centers for Disease Control and Prevention (CDC), states that the disease is 2-4 times more frequent among women than men, which majorly diagnosed at the age of around 45 years old.

Major players are focused on drug launches and regulatory approvals, which is expected to propel the market growth over the forecast period. For instance, in September 2019, United Therapeutics received the New Drug Application (NDA) approval by the U.S. Food and Drug Administration (FDA), for the drug, Trevyent. Trevyent is a drug device combination product, which comprise PatchPump technology that enables treprostilin administration by subcutaneous route. Moreover, in October 2019, United Therapeutics received an approval from the U.S. Food and Drug Administration (FDA) for Orenitram, treprostilin tablets. The tablets are expected to delay the progression of pulmonary arterial hypertension disease.

Browse 39 Market Data Tables and 25 Figures spread through 163 pages and in-depth TOC on 'Pulmonary Arterial Hypertension Market’- global forecast to 2027, by Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), by Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)'

To know the latest trends and insights prevalent in the Pulmonary Arterial Hypertension Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pulmonary-arterial-hypertension-pah-market-203

North America is expected to hold a dominant position in the pulmonary arterial hypertension market, owing to rising cases of pulmonary arterial hypertension and ongoing development and regulatory approvals for the associated drugs, which in turn is expected to fuel growth of the regional market over the forecast period. For instance, according to the CVS Health, the article published in April 2018 reports that pulmonary arterial hypertension is considered as a deadly disease, which affects between 10,000 and 20,000 people in the U.S. and it affects women mostly. According to the same source, pulmonary arterial hypertension is a progressive condition, if remained untreated, around 70% of patients may survive for a year after diagnosis and only about one-third make it to 5 years.

Moreover, several major players in the market are focusing on developing and gaining regulatory approvals of the product, which is expected to facilitate growth of the market over the forecast period. For instance, in March 2019, the U.S. Food & Drug Administration approved the very first generics drug for pulmonary arterial hypertension (PAH), Ambrisentan (Letairis).

Key Takeaways of the Pulmonary Arterial Hypertension Market:

  • The global pulmonary arterial hypertension market is expected to exhibit a CAGR of 5.9% over the forecast period, owing to rising cases that leads to pulmonary arterial hypertension which includes, congestive heart failure, pulmonary embolism, and others. For instance, according to the American College of Cardiology Foundation published an article Heart Disease and Stroke Statistics-2019, a report from the American Heart Association, which states that around 6.2 million U.S. adults had heart failure (HF) in 2013-2016, whereas, in 2014, atrial fibrillation and pulmonary embolism was the principal diagnosis in approximately 454,000 and 178,000 respectively in U.S. hospitalizations.
  • Among drug type, endothelin receptor antagonists (ERAs) segment held a dominant position in the pulmonary arterial hypertension market in 2018, owing to the FDA approvals, which is expected to propel the market growth. For instance, in September 2017, the U.S. Food & Drug Administration (FDA) approved Tracleer (bosentan) for the treatment of pediatric pulmonary arterial hypertension (PAH). This drug is approved for the pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR).
  • Companies operating in the global pulmonary arterial hypertension market include United Therapeutics Corporation, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company, Limited